Disease · HP_0012378
Fatigue
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Fatigue. Diseases, record HP_0012378. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012378
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Fatigue
- Open Targets ID
- HP_0012378
- Other names
- Tired, Tiredness
- Highest stage of its drugs
- Approval, for 2 of its 92 drugs, from DailyMed and TTD
Source Open Targets
Drugs92
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FERRIC OXYHYDROXIDE | CHEMBL4802224 | Small molecule | Approval | TTD | 2 | 1 | 0 | Drugs and targets |
| POLYVINYL ALCOHOL | CHEMBL3559671 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| MODAFINIL | CHEMBL1373 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 12 | Drugs and targets |
| METHYLPHENIDATE | CHEMBL796 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| EPOETIN ALFA | CHEMBL1201565 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| AMANTADINE | CHEMBL660 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GINSENG, AMERICAN | CHEMBL2109196 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets | |
| CHOLECALCIFEROL | CHEMBL1042 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 92
See all 92 drugsTargets181
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A3 | Sodium-dependent dopamine transporter | 6 | Dopamine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| SLC6A2 | Sodium-dependent noradrenaline transporter | 5 | Norepinephrine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 3 | Phosphodiesterase 5A inhibitor | Unknown | https://conductscience.org/library/genes/8654 | Drugs and targets |
| ADRA2A | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor | 2 | Adrenergic receptor agonist; Adrenergic receptor alpha-2 antagonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist | Phase 3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Unknown | https://conductscience.org/library/genes/1268 | Drugs and targets |
| EPOR | Erythropoietin receptor | 2 | Erythropoietin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2057 | Drugs and targets |
1 to 10 of 181
See all 181 targetsTrials103
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00719563 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | Phase 3 | 364 | 2014-08-06 | Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific | GINSENG, AMERICAN | Its record names the disease | ClinicalTrials.gov |
| NCT00424099 | Methylphenidate and a Nursing Telephone Intervention for Fatigue | Phase 2/3 | 197 | 2023-06-01 | Advanced Cancer, Fatigue | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT01956279 | Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI) | Phase 2 | 170 | 2020-05-01 | Fatigue, Musculoskeletal Pain, Cognitive Decline | PREGNENOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT04526665 | Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) | Phase 3 | 161 | 2024-09-05 | Primary Biliary Cirrhosis | ELAFIBRANOR | Its record names the disease | ClinicalTrials.gov |
| NCT00376675 | Methylphenidate in Treating Patients With Fatigue Caused by Cancer | Phase 3 | 148 | 2014-10-10 | Fatigue, Unspecified Adult Solid Tumor, Protocol Specific | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
| NCT03185065 | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Phase 3 | 141 | 2020-10-19 | Fatigue in Multiple Sclerosis | AMANTADINE, METHYLPHENIDATE, MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT01091974 | Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy | Phase 2 | 138 | 2015-03-13 | Insomnia, Fatigue, Breast Cancer | ARMODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT01303835 | Low Dose Naltrexone for Glioma Patients | Phase 2 | 110 | 2015-06-26 | Malignant Glioma | NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT01500096 | American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial | Phase 2 | 96 | 2018-06-12 | HIV/AIDS-associated Fatigue | GINSENG, AMERICAN | Its record names the disease | ClinicalTrials.gov |
| NCT02728752 | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) | Phase 3 | 95 | 2021-04-21 | Dermatomyositis | HUMAN IMMUNOGLOBULIN G | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 103
See all 103 trialsComparisons in its trials45
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ginseng vs Placebo: serious adverse events | 1 of 168 | 5 of 169 | 337 | NCT00719563 | Trial comparisons |
| Pregnenolone (Arm 1) vs Placebo (Arm 2): deaths from any cause | 1 of 82 | 0 of 88 | 170 | NCT01956279 | Trial comparisons |
| Pregnenolone (Arm 1) vs Placebo (Arm 2): serious adverse events | 1 of 82 | 0 of 88 | 170 | NCT01956279 | Trial comparisons |
| Elafibranor 80 mg vs Placebo: deaths from any cause | 2 of 108 | 0 of 53 | 161 | NCT04526665 | Trial comparisons |
| Elafibranor 80 mg vs Placebo: serious adverse events | 11 of 108 | 7 of 53 | 161 | NCT04526665 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: deaths from any cause | 0 of 95 | 0 of 48 | 143 | NCT02728752 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: serious adverse events | 14 of 95 | 2 of 48 | 143 | NCT02728752 | Trial comparisons |
| Methylphenidate vs Placebo: serious adverse events | 0 of 68 | 0 of 69 | 137 | NCT00376675 | Trial comparisons |
| Ginseng vs Placebo: serious adverse events | 0 of 56 | 0 of 56 | 112 | NCT00754832 | Trial comparisons |
| Naltrexone vs Placebo: serious adverse events | 12 of 54 | 17 of 56 | 110 | NCT01303835 | Trial comparisons |
1 to 10 of 45
See all 45 comparisons in its trialsPapers from its trials49
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012378
GET https://conductscience.org/api/diseases/v1/HP_0012378/drugs?page=2